Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERAS-404 in BCG-Primed Infants
NCT01861730Phase 2Completed
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Jul 2013
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of H4:IC31 in Tuberculosis (TB) (7 cohorts), sponsored by Aeras Global Vaccine Foundation. Primary endpoint: Safety of AERAS-404. Started Jul 2013; status: completed.
02
Drugs
H4:IC31
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01861730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861730.